X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES SHASUN PHARMA SUVEN LIFESCIENCES/
SHASUN PHARMA
 
P/E (TTM) x 18.8 123.9 15.2% View Chart
P/BV x 3.7 8.5 43.0% View Chart
Dividend Yield % 0.6 0.2 266.7%  

Financials

 SUVEN LIFESCIENCES   SHASUN PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
SHASUN PHARMA
Mar-14
SUVEN LIFESCIENCES/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs25194 266.2%   
Low Rs15546 339.9%   
Sales per share (Unadj.) Rs49.1214.2 22.9%  
Earnings per share (Unadj.) Rs9.75.3 182.1%  
Cash flow per share (Unadj.) Rs11.415.8 72.0%  
Dividends per share (Unadj.) Rs1.501.00 150.0%  
Dividend yield (eoy) %0.71.4 51.7%  
Book value per share (Unadj.) Rs60.353.3 113.0%  
Shares outstanding (eoy) m127.2856.62 224.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.10.3 1,265.6%   
Avg P/E ratio x20.913.1 159.4%  
P/CF ratio (eoy) x17.84.4 403.1%  
Price / Book Value ratio x3.41.3 256.8%  
Dividend payout %15.418.7 82.4%   
Avg Mkt Cap Rs m25,8253,958 652.5%   
No. of employees `0001.1NA-   
Total wages/salary Rs m6132,164 28.3%   
Avg. sales/employee Rs Th5,832.6NM-  
Avg. wages/employee Rs Th571.5NM-  
Avg. net profit/employee Rs Th1,153.8NM-  
INCOME DATA
Net Sales Rs m6,25312,127 51.6%  
Other income Rs m233229 101.5%   
Total revenues Rs m6,48512,356 52.5%   
Gross profit Rs m1,9821,009 196.4%  
Depreciation Rs m213594 35.9%   
Interest Rs m46415 11.2%   
Profit before tax Rs m1,955230 851.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m718-73 -987.7%   
Profit after tax Rs m1,237302 409.4%  
Gross profit margin %31.78.3 380.9%  
Effective tax rate %36.7-31.7 -116.0%   
Net profit margin %19.82.5 794.0%  
BALANCE SHEET DATA
Current assets Rs m5,6226,884 81.7%   
Current liabilities Rs m1,1688,456 13.8%   
Net working cap to sales %71.2-13.0 -549.7%  
Current ratio x4.80.8 591.5%  
Inventory Days Days8162 132.1%  
Debtors Days Days36108 33.4%  
Net fixed assets Rs m3,3254,970 66.9%   
Share capital Rs m127113 112.4%   
"Free" reserves Rs m7,5472,875 262.5%   
Net worth Rs m7,6743,020 254.1%   
Long term debt Rs m141,817 0.8%   
Total assets Rs m9,13513,347 68.4%  
Interest coverage x43.21.6 2,782.8%   
Debt to equity ratio x00.6 0.3%  
Sales to assets ratio x0.70.9 75.3%   
Return on assets %14.05.4 261.4%  
Return on equity %16.110.0 161.1%  
Return on capital %26.013.3 195.4%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m5,0665,843 86.7%   
Fx outflow Rs m2,0012,173 92.1%   
Net fx Rs m3,0653,669 83.5%   
CASH FLOW
From Operations Rs m699398 175.9%  
From Investments Rs m-6-1,635 0.4%  
From Financial Activity Rs m-5771,309 -44.1%  
Net Cashflow Rs m11671 163.3%  

Share Holding

Indian Promoters % 63.4 39.2 161.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 3.6 -  
FIIs % 0.0 17.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 39.6 92.2%  
Shareholders   37,287 20,750 179.7%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 234 Points Higher; Healthcare and Realty Stocks Rally(Closing)

After opening the day on a flat note, Indian share markets witnessed buying interest during closing hours and ended higher.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

SUVEN LIFE Announces Quarterly Results (4QFY18); Net Profit Up 56.0% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SUVEN LIFE has posted a net profit of Rs 625 m (up 56.0% YoY). Sales on the other hand came in at Rs 2 bn (up 18.6% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jul 16, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS